[ad_1]
WIXOM, Michigan, December 13, 2022—(BUSINESS WIRE)–Rockwell Medical, Inc. (“Rockwell” or the “Company”) (Nasdaq: RMTI ), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and kidney-related diseases, announced that the company is adding new jobs in the Minnesota region. Rockwell began supplying these clinics with its hemodialysis concentrates on December 5, 2022, expects to have all clinics on board by January 1, 2023, and expects to generate over $1 million in revenue in the first year.
“Rockwell is focused on growing the hemodialysis concentrates business throughout the United States and around the world.” Accordingly, we are pleased to announce that we are expanding our distribution capabilities west into Minnesota and supplying an additional 3,000 dialysis patients with our life-sustaining hemodialysis concentrate products,” said Dr. Mark Strobeck, President and CEO of Rockwell Medical. “We are excited to work more closely with our partner to support their dialysis centers and the patients they serve.”
Rockwell is the second largest supplier of life-sustaining hemodialysis concentrates to dialysis clinics in the United States and is one of only two suppliers with the manufacturing scalability and transportation infrastructure to service over 7,500 dialysis clinics in the United States, along with select international markets. In the United States, the in-center hemodialysis concentrate market is currently valued at $380 million and is expected to grow to approximately $500 million by 2026, primarily due to the increasing number of patients suffering from end-stage renal disease. Rockwell is an indispensable player in this large and growing market and we believe it is well positioned to achieve annual revenues of $100 million over the next few years.
About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and kidney-related diseases. Rockwell is an innovative leader in the manufacture and supply of a portfolio of hemodialysis products, including concentrates (solutions and powders) and related excipients, to dialysis providers in the United States and around the world. Rockwell is the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. The company is committed to providing the hemodialysis community with the highest quality products backed by the most reliable shipping service in the industry. For more information, visit www.RockwellMed.com.
Forward-looking statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of federal securities laws. Words such as “may,” “could,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “can,” “would,” “develop,” “plan,” “potential,” “anticipate,” “anticipate,” “project,” “intend,” “look forward to,” “remain confident,” or the negative of these terms and similar expressions, or statements regarding intent, belief or current expectations are forward-looking statements. There can be no assurance that: Rockwell Medical will be able to achieve revenue projections, planned cost savings from its concentrates operations or achieve other components of its strategy; either the center market for hemodialysis concentrates will increase or Rockwell Medical will be able to access the anticipated market opportunity. Although Rockwell Medical believes that these forward-looking statements are reasonable, you should not place undue reliance on such forward-looking statements, which are based on information available to us as of the date of this release. These forward-looking statements are based on current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical’s SEC filings), many of which are beyond our control and are subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to, those risks discussed in more detail in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2021, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.
See the original version on businesswire.com: https://www.businessvire.com/nevs/home/20221213005463/en/
Contacts
Heather R. Hunter
SVP, Chief Corporate Affairs Officer
(248) 432-1362
IR@RockvellMed.com
[ad_2]
Source link
